Beta | p Value | HR | 95% CI for Exp (B) | ||
Lower | Upper | ||||
Panel A: Crude model | |||||
Time-dependent covariate (DAS28) | 0.113 | 0.119 | 1.120 | 0.972 | 1.290 |
Age | 0.064 | <0.001 | 2.010 | 1.344 | 3.005 |
Gender | 0.698 | 0.001 | 1.066 | 1.047 | 1.085 |
Panel B: Corrected model | |||||
Time-dependent covariate (DAS28) | 0.165 | 0.032 | 1.179 | 1.014 | 1.370 |
Age | 0.062 | <0.001 | 1.064 | 1.044 | 1.084 |
Gender | 0.725 | 0.001 | 2.065 | 1.365 | 3.123 |
Hypertension baseline | 1.036 | <0.001 | 2.818 | 1.673 | 4.745 |
HDL-c | −0.736 | 0.043 | 0.466 | 0.222 | 0.977 |
CVD medication* | −0.515 | 0.026 | 0.597 | 0.379 | 0.940 |
DAS28 baseline | 0.034 | 0.687 | 1.035 | 0.877 | 1.220 |
Panel C: Corrected model | |||||
Time-dependent covariate (DAS28 <3.2) | −0.431 | 0.044 | 0.650 | 0.427 | 0.989 |
Age | 0.064 | <0.001 | 1.066 | 1.046 | 1.087 |
Gender | 0.736 | 0.001 | 2.088 | 1.372 | 3.177 |
Hypertension | 0.977 | <0.001 | 2.656 | 1.547 | 4.559 |
HDL-c | −1.113 | 0.009 | 0.329 | 0.142 | 0.758 |
LDL-c | 0.177 | 0.097 | 1.193 | 0.969 | 1.470 |
CVD medication* | −0.541 | 0.022 | 0.582 | 0.366 | 0.925 |
CRP | −0.001 | 0.538 | 0.999 | 0.994 | 1.003 |
*Anti-hypertensive medication, lipid lowering medication.
CRP, C-reactive protein; DAS28, 28-joint disease activity score; HDL-c, high-density lipoprotein cholesterol; LDL-c, low-density lipoprotein cholesterol.